ea0029p788 | Endocrine tumours and neoplasia | ICEECE2012
Seregni E.
, Vincenzo M.
, Braud De F.
, Buzzoni R.
, Marco M.
, Coliva A.
, Pascali C.
, Mallia A.
, Bombardieri E.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of β-emitting radioisotopes has been reported.Aim: Ongoing study to evaluate efficacy and toxicity of combination treatment with 4 cycles of radiolabeled DOTATATE, alternating 177Lu and 90Yin patients with metastasised NETs expressing SRs refract...